NY-ESO-1eTCR

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameNY-ESO-1eTCR
Drug Alias NameNYCE T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsAnti-NY-ESO-1
TargetsCancer/testis antigen 1
Therapy Area/IndicationsMultiple MyelomaMelanomaSarcoma, Synovial +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTmunity Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences IncUniversity Of Pennsylvania
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaMelanomaSarcoma, Synovial +[4] 

Other Information

ATC CodeN/A
Related LinksN/A